Mass. Movers

Insiders boosting their stake in Aegerion

Aegerion develops drugs to treat rare diseases.

Aegerion develops drugs to treat rare diseases.


The Motley Fool, noting one way to forecast a stock’s direction is to monitor insiders’ share purchases, reported that Cambridge-based Aegerion Pharmaceuticals Inc. has seen “significant insider and institutional interest.” In the last 6 months, insiders have acquired an additional 624,767 shares, bringing total insider holdings to 5.8 million shares, an 11 percent increase. During the same time, institutions increased their holdings by 2.1 million shares, or 10 percent.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of